Published in Blood on January 29, 2009
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma | NCT01248455
Optimising Renal Outcome in Myeloma Renal Failure (OPTIMAL) | NCT02424851
Lenalidomide Maintenance Therapy for Multiple Myeloma | NCT01675141
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood (2011) 2.54
Treatment of multiple myeloma. Nat Rev Clin Oncol (2011) 2.46
Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest (2012) 2.24
Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia (2011) 2.12
Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood (2010) 2.12
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood (2013) 1.98
Obesity is associated with an increased risk of monoclonal gammopathy of undetermined significance among black and white women. Blood (2010) 1.98
Chromothripsis identifies a rare and aggressive entity among newly diagnosed multiple myeloma patients. Blood (2011) 1.97
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
The Haematological Malignancy Research Network (HMRN): a new information strategy for population based epidemiology and health service research. Br J Haematol (2009) 1.67
Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood (2013) 1.64
Approach to the treatment of multiple myeloma: a clash of philosophies. Blood (2011) 1.57
European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. Haematologica (2014) 1.57
Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia (2013) 1.54
Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica (2012) 1.53
Uncovering the biology of multiple myeloma among African Americans: a comprehensive genomics approach. Blood (2013) 1.53
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Increased serum free light chains precede the presentation of immunoglobulin light chain amyloidosis. J Clin Oncol (2014) 1.42
Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia (2012) 1.41
Myeloma as a model for the process of metastasis: implications for therapy. Blood (2012) 1.36
Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol (2010) 1.36
Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol (2012) 1.35
Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood (2009) 1.30
Can multiple myeloma become a curable disease? Haematologica (2011) 1.22
Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol (2012) 1.21
Polycomb target genes are silenced in multiple myeloma. PLoS One (2010) 1.21
Patterns of survival and causes of death following a diagnosis of monoclonal gammopathy of undetermined significance: a population-based study. Haematologica (2009) 1.19
Haematological cancer: Redefining myeloma. Nat Rev Clin Oncol (2012) 1.17
Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer (2009) 1.12
MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct (2011) 1.10
Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood (2010) 1.09
Prevention of progression in monoclonal gammopathy of undetermined significance. Clin Cancer Res (2009) 1.08
Evidence for ongoing DNA damage in multiple myeloma cells as revealed by constitutive phosphorylation of H2AX. Leukemia (2011) 1.08
γ-H2AX and other histone post-translational modifications in the clinic. Biochim Biophys Acta (2012) 1.07
Multiple Myeloma: Diagnosis and Treatment. Mayo Clin Proc (2016) 1.07
MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression. BMC Cancer (2014) 1.06
Inherited genetic susceptibility to multiple myeloma. Leukemia (2013) 1.04
Molecular pathogenesis of multiple myeloma: basic and clinical updates. Int J Hematol (2013) 1.04
Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood (2015) 1.04
Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma. Haematologica (2010) 1.04
Extramedullary involvement in multiple myeloma. Haematologica (2012) 1.03
Pathogenesis of monoclonal gammopathy of undetermined significance and progression to multiple myeloma. Semin Hematol (2011) 1.01
Many multiple myelomas: making more of the molecular mayhem. Hematology Am Soc Hematol Educ Program (2011) 1.00
A replicative self-renewal model for long-lived plasma cells: questioning irreversible cell cycle exit. Front Immunol (2013) 0.99
The role of epigenetics in the biology of multiple myeloma. Blood Cancer J (2014) 0.99
A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia (2012) 0.99
The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance. Haematologica (2010) 0.98
Immunological dysregulation in multiple myeloma microenvironment. Biomed Res Int (2014) 0.98
Epigenetic modulating agents as a new therapeutic approach in multiple myeloma. Cancers (Basel) (2013) 0.97
A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood (2012) 0.97
Current and future imaging modalities for multiple myeloma and its precursor states. Leuk Lymphoma (2011) 0.97
The genetic architecture of multiple myeloma. Adv Hematol (2014) 0.96
Cellular mechanisms of multiple myeloma bone disease. Clin Dev Immunol (2013) 0.96
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: a review of the current understanding of epidemiology, biology, risk stratification, and management of myeloma precursor disease. Clin Cancer Res (2012) 0.96
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol (2016) 0.94
Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study. Haematologica (2011) 0.94
Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas. PLoS One (2010) 0.94
MicroRNA theragnostics for the clinical management of multiple myeloma. Leukemia (2013) 0.93
Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma (2010) 0.93
Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia (2013) 0.92
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma. Nat Commun (2015) 0.92
Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis. Clin Lymphoma Myeloma Leuk (2014) 0.91
Genetics of multiple myeloma: another heterogeneity level? Blood (2015) 0.91
Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? Oncotarget (2015) 0.91
Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia (2012) 0.91
Incidence of monoclonal gammopathy of undetermined significance and estimation of duration before first clinical recognition. Mayo Clin Proc (2012) 0.90
Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies. Haematologica (2014) 0.89
Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget (2014) 0.89
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun (2016) 0.89
The significance of monoclonal gammopathy of undetermined significance. Haematologica (2009) 0.88
Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12,482 persons from the National Health and Nutritional Examination Survey. Leukemia (2014) 0.88
The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network. Haematologica (2014) 0.88
Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. Oncotarget (2012) 0.88
Mechanisms of multiple myeloma bone disease. Bonekey Rep (2012) 0.88
Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study. Cancer Prev Res (Phila) (2013) 0.87
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
Personal and family history of immune-related conditions increase the risk of plasma cell disorders: a population-based study. Blood (2011) 0.86
Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. J Hematol Oncol (2010) 0.86
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment. Cell Cycle (2013) 0.86
The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies. Blood Cancer J (2015) 0.86
Clinical course of light-chain smouldering multiple myeloma (idiopathic Bence Jones proteinuria): a retrospective cohort study. Lancet Haematol (2014) 0.86
Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case-control study using electronic records. Br J Gen Pract (2015) 0.85
Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. Blood (2011) 0.84
The skinny on obesity and plasma cell myeloma: a review of the literature. Bone Marrow Transplant (2014) 0.84
Precursors to lymphoproliferative malignancies. Cancer Epidemiol Biomarkers Prev (2013) 0.84
Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management. Expert Rev Mol Diagn (2011) 0.84
MGUS prevalence in an ethnically Chinese population in Hong Kong. Blood (2013) 0.84
The current status of minimal residual disease assessment in myeloma. Leukemia (2014) 0.83
Can tissue-based immune markers be used for studying the natural history of cancer? Ann Epidemiol (2012) 0.83
Molecular imaging in myeloma precursor disease. Semin Hematol (2011) 0.83
Implications of heterogeneity in multiple myeloma. Biomed Res Int (2014) 0.82
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120). Haematologica (2015) 0.82
Effect of HM910, a novel camptothecin derivative, on the inhibition of multiple myeloma cell growth in vitro and in vivo. Am J Cancer Res (2015) 0.82
Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Curr Hematol Malig Rep (2010) 0.82
Discovering the meaning of monoclonal gammopathy of undetermined significance: current knowledge, future challenges. Transl Med UniSa (2014) 0.82
Early lymphoid lesions: conceptual, diagnostic and clinical challenges. Haematologica (2014) 0.82
Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma. Leukemia (2016) 0.81
Longitudinal data analysis for discrete and continuous outcomes. Biometrics (1986) 60.93
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Multiple myeloma. N Engl J Med (2004) 10.81
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer (2002) 5.30
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood (2006) 3.64
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. Am J Med (1978) 3.08
Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood (2001) 2.93
Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood (2003) 2.68
Multiple myeloma, chronic lymphocytic leukaemia and associated precursor diseases. Br J Haematol (2007) 1.48
Pathogenesis and progression of monoclonal gammopathy of undetermined significance. Leukemia (2008) 1.39
Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clin Proc (2007) 1.27
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet (2010) 23.08
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Six new loci associated with body mass index highlight a neuronal influence on body weight regulation. Nat Genet (2008) 22.35
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature (2010) 20.01
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Identification of ten loci associated with height highlights new biological pathways in human growth. Nat Genet (2008) 16.25
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Replicating genotype-phenotype associations. Nature (2007) 16.11
Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet (2008) 15.94
Improved survival in multiple myeloma and the impact of novel therapies. Blood (2007) 12.70
Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol (2011) 12.10
International staging system for multiple myeloma. J Clin Oncol (2005) 11.29
Multiple myeloma. N Engl J Med (2004) 10.81
Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc (2003) 9.96
A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med (2002) 8.63
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med (2007) 8.41
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med (2006) 7.24
Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell (2007) 7.24
Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS (2006) 7.08
Prediction error estimation: a comparison of resampling methods. Bioinformatics (2005) 6.41
A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet (2013) 6.19
Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med (2007) 6.07
Multiple myeloma. Blood (2008) 5.88
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood (2005) 5.82
On criteria for evaluating models of absolute risk. Biostatistics (2005) 5.71
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet (2009) 5.62
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med (2014) 5.08
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Quality control and quality assurance in genotypic data for genome-wide association studies. Genet Epidemiol (2010) 4.83
Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet (2010) 4.75
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst (2011) 4.69
Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood (2003) 4.67
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood (2005) 4.48
Pathway analysis by adaptive combination of P-values. Genet Epidemiol (2009) 4.48
Clonal competition with alternating dominance in multiple myeloma. Blood (2012) 4.39
POEMS syndrome: definitions and long-term outcome. Blood (2002) 4.35
Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med (2010) 4.30
B-cell clones as early markers for chronic lymphocytic leukemia. N Engl J Med (2009) 4.27
Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem (2002) 4.24
Hematotoxicity in workers exposed to low levels of benzene. Science (2004) 4.19
Genome-wide association study of circulating vitamin D levels. Hum Mol Genet (2010) 4.07
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD. PLoS Genet (2010) 3.91
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. PLoS One (2008) 3.87
Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet (2009) 3.76
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology (2009) 3.73
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol (2008) 3.60
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol (2004) 3.43
Tumor immunobiological differences in prostate cancer between African-American and European-American men. Cancer Res (2008) 3.39
New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol (2012) 3.35
Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood (2002) 3.34
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Utilization of surveillance colonoscopy in community practice. Gastroenterology (2009) 3.33
Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33
The association of telomere length and cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev (2011) 3.29
Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood (2005) 3.25
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst (2006) 3.17